A Study To Evaluate The Effect Of Food On The Behavior of Tofacitinib Modified Release 22 Milligram Tablets In Healthy Volunteers

Study Overview
=================
Brief Summary
-----------------
This study will evaluate the drug behavior and safety of a single dose of the 22 milligram tofacitinib (CP-690,550) modified-release formulation in 18 healthy volunteers when taken after eating a high fat meal (the effect of food). This will be compared to the drug behavior and safety of a single dose of the 22 milligram tofacitinib (CP-690,550) modified-release formulation when taken after a 10 hour fast.

Official Title
-----------------
A Phase 1, Randomized, Open Label, Single Dose, 2 Period Crossover Study To Evaluate The Effect Of Food On The Pharmacokinetics Of Tofacitinib Modified Release (mr) 22 Mg Tablets In Healthy Volunteers

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: Tofacitinib MR 22 mg (Fed)
* Drug: Tofacitinib MR 22 mg (Fasted)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy male volunteers and/or healthy female volunteers of non-childbearing potential who are 18 to 55 years of age; Healthy volunteers with no evidence of active or latent or inadequately treated tuberculosis. Exclusion Criteria: Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease; Clinically significant infections within the past 3 months

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Tofacitinib MR 22 mg Fed<br>Single dose of tofacitinib MR 22 mg administered under fed conditions | Drug: Tofacitinib MR 22 mg (Fed)<br>* A single dose of tofacitinib modified release 22 mg tablet after receiving the standard FDA high-fat/high-calorie meal<br>|
| Experimental: Tofacitinib MR 22 mg Fasted<br>Single dose of tofacitinib MR 22 mg administered under fasted conditions | Drug: Tofacitinib MR 22 mg (Fasted)<br>* A single dose of tofacitinib modified release 22 mg tablet after an overnight fast of 10 hours<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AUC inf | Area under the plasma concentration-time profile from time zero to infinity (AUCinf). | 48 hours post dose | 
| AUC last | Area under the plasma concentration-time profile from time zero to time of last identifiable quantitation (AUC last). | 48 hours post dose | 
| Cmax | Maximum observed plasma concentration (Cmax). | 48 hours post dose | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to Reach Maximum Observed Plasma Concentration (Tmax) |  | 48 hours post dose | 
| Plasma Decay Half-Life (t 1/2) | Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. | 48 hours post dose | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
food effect, pharmacokinetics, healthy volunteers